Weekend Report — Opportunities I See
🚀 High-Probability Explosive Gains Setups (Low Downside Focus)
Next Week Catalysts: April 13–17, 2026
Data as of April 11, 2026 (Weekend)
Built for scanner-style momentum trading (ASTS / ALLO / WULF-type runs)
📊 Quick Catalyst Overview
| Ticker | Catalyst Date | Event | Est. Positive Probability |
|---|---|---|---|
| TVTX | April 13 | PDUFA – FILSPARI sNDA (FSGS) | 65–75% |
| IDYA | April 13 | Phase 2/3 topline data (OptimUM-02) | 50–65% |
| MGTX | April 16 | 3-year durability data + update | 70–85% |
| ASMB | April 17 | Phase 1b data (HSV-2, Gilead partnered) | 75–90% |
| KURA | April 17 | Updated combo oncology data + call | 60–75% |
📈 Trading Game Plan (Core Rules)
• Position size small: 1–2% max portfolio risk per trade
• Entries: Near support / pre-catalyst consolidation zones
• Stops: Hard stops below key support (no exceptions)
• Profit taking: Scale out (50%) on first major move
• Let runners ride with trailing stops
⚠️ Expect volatility spikes around catalysts — monitor volume, sentiment, and real-time flow.
🔬 Detailed Setup Breakdown
TVTX – Travere Therapeutics
| Entry Zone | $28.50 – $29.50 |
| Stop Loss | $27.50 |
| Targets | $35 (partial) / $42 (full) |
| Upside | +30–60% |
| Risk | ~5–7% |
| R/R | ~1:7+ |
IDYA – Ideaya Biosciences
| Entry | $29.50 – $31 |
| Stop | $28.00 |
| Targets | $40 / $48–51 |
| Upside | +60%+ |
| Risk | ~8% |
MGTX – MeiraGTx
| Entry | $8.50 – $9.00 |
| Stop | $7.50 |
| Targets | $16 / $23 |
| Upside | +150%+ |
| Risk | ~16% |
ASMB – Assembly Biosciences
| Entry | $28 – $29 |
| Stop | $26 |
| Targets | $35 / $42–46 |
| Upside | +45–60% |
KURA – Kura Oncology
| Entry | $8.50 |
| Stop | $7.50 |
| Targets | $16 / $26–33 |
| Upside | +200%+ |
⚠️ Risk Notes & Public Disclaimer
• Highest probability setups: ASMB, MGTX
• Highest asymmetry: KURA, MGTX
• Tightest defined risk: TVTX
All trades are event-driven and highly volatile.
This content is for informational and educational purposes only and does not constitute financial, investment, or trading advice. The author is not a licensed financial advisor. All trading involves risk, including the potential loss of principal. Biotech catalyst trades are especially volatile and can result in rapid gains or losses.
Probability estimates are subjective and based on publicly available information, historical trends, and market sentiment — they are not guarantees of outcome. Always conduct your own due diligence and consult with a qualified financial professional before making investment decisions.
The author may hold positions in the securities mentioned. Prices, targets, and setups are approximate and may change without notice. Use proper risk management and only trade with capital you can afford to lose.
Comments
Post a Comment